Abstract
The disintegrin metalloprotease ADAM9 is a cell-surface protease that can shed the ectodomain of membrane protein substrates. Dysregulated ADAM9 activity has been implicated in several diseases such as solid tumors, autoimmunity, inflammatory diseases, and COVID-19. Despite its importance, the substrates and targets of ADAM9 in normal and pathological processes are poorly understood. Here, we developed an integrative proteotranscriptomics approach to systematically identify the transcriptional and post-transcriptional targets of ADAM9 in HCT116 cells, which have a stable diploid karyotype suitable for omics analyses. Using this approach, we uncovered major signaling pathways downstream of ADAM9, including the oncogenic mTOR pathway and the tumor suppressor FOXO pathway. We also identified several direct and indirect substrates for ADAM9, which may mediate the pathophysiological roles of this protease. This study provides new mechanistic insights into the function of ADAM9 as well as a method that can be applied to other membrane proteases.
Full text
1,422 characters
· extracted from
oa-html
· click to expand
Abstract
Membrane protein shedding is a key regulatory mechanism for cell signaling and adhesion, and dysregulated shedding is associated with diseases. Many membrane proteases can catalyze shedding, but the substrate spectra and downstream targets of these “sheddases” remain largely elusive. While secretomics-based methods have been applied to the systematic identification of sheddase substrates, these methods are not always effective and do not provide much information on downstream targets. Here we developed an integrative proteotranscriptomics approach to uncover the transcriptional and post-transcriptional targets of the disintegrin metalloproteinase ADAM9, a sheddase that has been implicated in solid tumors, autoimmunity, inflammatory diseases and COVID-19. This systematic approach revealed signaling pathways downstream of ADAM9, including the oncogenic mTOR and tumor suppressor FOXO pathways. We further identified several direct and indirect substrates for ADAM9, which may mediate the pathophysiological roles of ADAM9 in various diseases. Of note, some of these substrates are difficult to detect by secretomics. This new approach can be applied to other sheddases to systematically identify their substrates and targets.
Full Text Availability
The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.